Skip to main content

Table 2 ERβ1 expression levels by morphology and subtype

From: ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

 

ERβ1 expression

Cohort 1 n = 184**

Cohort 2 n = 68

n = 177

  

Nucleus

Cytoplasm

Nucleus

Cytoplasm

Nucleus

Cytoplasm

Molecular Subtype

  Luminal A (ERα +/ HER2 -/ Ki67 ≤ 10)

Neg/low

31 (18.3)

47 (25.5)

    

Moderate

18 (10.7)

3 (1.6)

    

High

1 (0.6)

0

    

  Luminal B (ERα +/ HER2 -/ Ki67 > 10)

Neg/low

59 (34.9)

76 (41.3)

    

Moderate

25 (14.8)

11 (6.0)

    

High

3 (1.8)

0

    

  Her2+

Neg/low

20 (11,8)

24 (13.0)

    

Moderate

7 (4.1)

3 (1.6)

    

High

0

0

    

  Triple Negative (ERα -/PR-/ HER2 -)

Neg/low

1 (0.6)

5 (2.7)

51 (75.0)

45 (66.2)

  

Moderate

4 (2.4)

0

17 (25.0)

21 (30.9)

  

High

0

0

0

2 (2.9)

  

Histologic Subtype

Ductal

Neg/low

93 (50.5)

120 (65.2)

39 (57.4)

34 (50.0)

28 (15.8)

0

Moderate

42 (22.8)

18 (9.8)

13 (19.1)

16 (23.5)

79 (44.6)

45 (25.4)

High

3 (1.6)

0

0

2 (2.9)

36 (20.3)

98 (55.4)

Lobular

Neg/low

18 (9.8)

26 (14.1)

0

0

1 (0.6)

0

Moderate

9 (4.9)

2 (1.1)

0

0

10 (5.7)

3 (1.7)

High

1 (0.5)

0

0

0

5 (2.8)

13 (7.3)

Other

Neg/low

10 (5.4)

18 (9.8)

12 (17.6)

11 (16.2)

3 (1.7)

1 (0.6)

Moderate

8 (4.4)

0

4 (5.9)

5 (7.4)

7 (4.0)

4 (2.3)

 

High

0

0

0

0

8 (4.5)

13 (7.3)

  1. *ki67 not performed **unable to determine molecular subtype in 15 Cohort 1 pts.